Novelna Inc. is a biotech start-up, pioneering accurate and affordable screening tests for early-stage cancer detection as well as metabolic (NASH) and neurological (MS) disorders. We have two principal pipelines, one blood the other urine-based.
Our core technology rests on a combination of deep proteomics and deep learning approaches; we hold IP for numerous biomarker panels and our platform approach enables us to produce IP-protected tests for other diseases and disorders of interest.